US Patent

US7196205 — Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors

Composition of Matter · Assigned to Genzyme Corp · Expires 2026-06-26 · 0y remaining

Vulnerability score 27/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects a novel synthesis method for ceramide-like inhibitors of UDP-glucose: N-acylsphingosine glucosyltransferase.

USPTO Abstract

Disclosed is a novel enantiomeric synthesis ceramide-like inhibitors of UDP-glucose: N-acylsphingosine glucosyltransferase. Also disclosed are novel intermediates formed during the synthesis.

Drugs covered by this patent

Patent Metadata

Patent number
US7196205
Jurisdiction
US
Classification
Composition of Matter
Expires
2026-06-26
Drug substance claim
Yes
Drug product claim
No
Assignee
Genzyme Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.